Studies older adults with advanced bladder cancer who cannot receive cisplatin
Looks at how a geriatric survey predicts outcomes in older adults with advanced bladder cancer.
Key facts
- Who runs it
- Dana-Farber Cancer Institute
- Where
- Boston, United StatesSee the site
- Trial code
- Registry title
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
- Status
- Recruiting
- People taking part
- 180 people, planned
- Started
- 5 Mar 2024
- Expected to end
- 1 Jan 2028
- Type of study
- Observational
- Treatments tested
- Geriatric-8 Survey
- National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18)
- Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
- Record updated
- 17 February 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for people aged 65 or older with advanced or metastatic bladder cancer (urothelial carcinoma) who cannot have cisplatin chemotherapy and are getting treatment.
- Age
- 65 years or older. Only 20% of all participants may be aged 65-70.
- Sex
- All sexes can join.
- Disease stage
- Bladder cancer that cannot be removed by surgery or has spread, proven to be urothelial carcinoma. Variant histology is allowed.
- Earlier treatment
- The primary oncologist must judge the person cannot have cisplatin. The person is getting chemotherapy (with or without immunotherapy maintenance), enfortumab vedotin-pembrolizumab, or immunotherapy alone.
Main reasons for not taking part
- Chooses not to have cancer treatment
- Gets care outside DFCI or DFCI affiliate sites
- Advanced cognitive impairment or cannot complete surveys
- Is receiving other investigational agents for this condition
The registry criteria, word for word
Show all 9 criteriaShow less
Who can take part
- Age ≥65-years-old (study will limit total enrollment of patients between ages 65-70 to 20% of the total study population)
- Unresectable or metastatic bladder cancer with histologically proven urothelial carcinoma. Any component of variant histology is allowed
- Cisplatin-ineligible as determined by the subject's primary oncologist
- Receiving treatment with chemotherapy (+/- immunotherapy maintenance), enfortumab vedotin-pembrolizumab combination therapy or immunotherapy alone
- Ability to understand and the willingness to sign a written informed consent document and to complete patient reported outcomes that will be in English or Spanish either alone or with assistance of study researcher or family
Who cannot take part
- Participants who are receiving any other investigational agents for this condition (if appropriate only)
- Subjects who elect to not undergo cancer-directed therapy
- Advanced cognitive impairment or inability to complete surveys
- Subjects obtaining their care outside of DFCI or DFCI affiliate sites
Where in United States
- Dana-Farber Cancer InstituteBoston, United StatesContact: Joaquim Bellmunt, MD, PhDTaking people
About the trial
What the trial wants to find out
The goal of this study is to better understand how to best treat participants with advanced bladder cancer who may not be able to tolerate all of the chemotherapy drugs that have been shown to be effective. In this study, investigators are assessing the role of the survey, the Geriatric-8, and its ability to predict outcomes in older participants undergoing cancer treatments. Additionally, investigators are evaluating the differential impact of treatments on quality of life in an older and at risk population.
The group in the trial
- Cisplatin-Ineligible Metastatic Bladder Cancer
Participants receiving standard of care non-cisplatin based therapy (carboplatin-based chemotherapy, enfortumab vedotin plus pembrolizumab or immunotherapy) and will complete study procedures as outlined below: * Baseline visit with questionnaires. * Complete surveys every 3 weeks by telephone or by in-office visit for 8 months. * Optional follow-up phone calls every 6 months for up to 3 years.
Treatment: Geriatric-8 Survey, National Comprehensive Cancer Network/Functional Assessment of Cancer Therapy Bladder Symptom Index-18 (FBISI-18), and Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE®)
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.
- Official title
- Management of Cisplatin-Ineligible Patients With Metastatic Bladder Cancer and The Role of Geriatric Assessments
- Plain-language title
- Studies older adults with advanced bladder cancer who cannot receive cisplatinGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 12 November 2026.
- Record updated
- 17 February 2026